DNA-aptamer targeting vimentin for tumor therapy in vivo.

In recent years, new prospects for the use of nucleic acids as anticancer drugs have been discovered. Aptamers for intracellular targets can regulate cellular functions and cause cell death or proliferation. However, intracellular aptamers have limited use for therapeutic applications due to their low bioavailability. In this work, we selected DNA aptamers to cell organelles and nucleus of cancer cells, and showed that an aptamer NAS-24 binds to vimentin and causes apoptosis of mouse ascites adenocarcinoma cells in vitro and in vivo. To deliver the aptamer NAS-24 inside cells, natural polysaccharide arabinogalactan was used as a carrier reagent. The mixture of arabinogalactan and NAS-24 was injected intraperitonealy for 5 days into mice with adenocarcinoma and inhibited adenocarcinoma growth more effectively than free arabinogalactan or the aptamer alone. The use of aptamers to intracellular targets together with arabinogalactan becomes a promising approach for anticancer therapy.

[1]  M. Roehrl,et al.  Glycoproteomic Analysis of Human Lung Adenocarcinomas Using Glycoarrays and Tandem Mass Spectrometry: Differential Expression and Glycosylation Patterns of Vimentin and Fetuin A Isoforms , 2009, The protein journal.

[2]  Q. Shen,et al.  RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells , 2009, Oncogene.

[3]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[4]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[5]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[6]  Sergey N Krylov,et al.  Aptamer-facilitated biomarker discovery (AptaBiD). , 2008, Journal of the American Chemical Society.

[7]  A. Al-Hendy,et al.  Gene therapy and uterine leiomyoma: a review. , 2006, Human reproduction update.

[8]  Ofer Levy,et al.  Systemic Stimulation of TLR2 Impairs Neonatal Mouse Brain Development , 2011, PloS one.

[9]  Xiaoling Zhang,et al.  Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.

[10]  Xun Sun,et al.  A cell-specific poly(ethylene glycol) derivative with a wheat-like structure for efficient gene delivery. , 2012, Molecular pharmaceutics.

[11]  H. Kijima,et al.  Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. , 2010, Biomedical research.

[12]  Johanna Ivaska,et al.  Novel functions of vimentin in cell adhesion, migration, and signaling. , 2007, Experimental cell research.

[13]  A. Ellington,et al.  Inhibition of Cell Proliferation by an Anti-EGFR Aptamer , 2011, PloS one.

[14]  D. Xie,et al.  Association of Vimentin overexpression and hepatocellular carcinoma metastasis , 2004, Oncogene.

[15]  Yury E. Glazyrin,et al.  Development of bacteriostatic DNA aptamers for salmonella. , 2013, Journal of medicinal chemistry.

[16]  Y. Sakaki,et al.  Refined human artificial chromosome vectors for gene therapy and animal transgenesis , 2010, Gene Therapy.

[17]  R. Juliano,et al.  Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides , 2008, Nucleic acids research.

[18]  B. Stefanovic,et al.  A Novel Role of Vimentin Filaments: Binding and Stabilization of Collagen mRNAs , 2011, Molecular and Cellular Biology.

[19]  J. Pin,et al.  Immature Human Dendritic Cells Express Asialoglycoprotein Receptor Isoforms for Efficient Receptor-Mediated Endocytosis1 , 2001, The Journal of Immunology.

[20]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[21]  Andrea Rentmeister,et al.  Cell-Specific Aptamers as Emerging Therapeutics , 2011, Journal of nucleic acids.

[22]  J. Brooks,et al.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma , 2009, BMC clinical pathology.

[23]  Kwangmeyung Kim,et al.  Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. , 2013, Molecular pharmaceutics.

[24]  H. Ulrich RNA aptamers: from basic science towards therapy. , 2006, Handbook of experimental pharmacology.

[25]  S. Shukla,et al.  Cytokeratin and Vimentin Expression in Breast Cancer , 2009 .

[26]  D. Liggitt,et al.  Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Dexi Liu,et al.  Computer-assisted hydrodynamic gene delivery. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[29]  Darija Muharemagic,et al.  Electrochemical differentiation of epitope-specific aptamers. , 2012, Analytical chemistry.

[30]  G. Christman,et al.  Gene therapy and reproductive medicine. , 2002, Fertility and sterility.

[31]  C. Lehr,et al.  Lectins and glycoconjugates in drug delivery and targeting. , 2004, Advanced drug delivery reviews.

[32]  Y. Barenholz,et al.  Polymers for DNA Delivery , 2005, Molecules.

[33]  F. Chen,et al.  Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis , 2001, Cell Death and Differentiation.

[34]  Y. Nakagawa,et al.  CpG island promoter methylation (CIHM) status of tumor suppressor genes correlates with morphological appearances of gastric cancer. , 2010, Anticancer research.

[35]  Baocun Sun,et al.  A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis , 2010, Journal of experimental & clinical cancer research : CR.

[36]  L. Wiebe,et al.  Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. , 2008, Current drug delivery.

[37]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[38]  Darija Muharemagic,et al.  Anti-Fab aptamers for shielding virus from neutralizing antibodies. , 2012, Journal of the American Chemical Society.

[39]  J. Foidart,et al.  Transactivation of Vimentin by β-Catenin in Human Breast Cancer Cells , 2003 .

[40]  A. Ellington,et al.  In Vitro Selection of RNA Aptamers to a Small Molecule Target , 2002, Current protocols in nucleic acid chemistry.

[41]  A. Satelli,et al.  Vimentin in cancer and its potential as a molecular target for cancer therapy , 2011, Cellular and Molecular Life Sciences.

[42]  P. Ray,et al.  Aptamers for Targeted Drug Delivery , 2010, Pharmaceuticals.

[43]  Wei Chen,et al.  Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. , 2010, American journal of translational research.

[44]  L. Josephson,et al.  Arabinogalactan for hepatic drug delivery. , 1994, Bioconjugate chemistry.

[45]  N. Hu,et al.  Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer , 2004, Oncogene.

[46]  X. Long,et al.  Vimentin affects the mobility and invasiveness of prostate cancer cells , 2008, Cell biochemistry and function.

[47]  R. Narain,et al.  Intracellular delivery of DNA and enzyme in active form using degradable carbohydrate-based nanogels. , 2012, Molecular pharmaceutics.

[48]  Michael Wirth,et al.  The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. , 2004, Advanced drug delivery reviews.

[49]  M. Yashiro,et al.  Clinical significance of vimentin-positive gastric cancer cells. , 2010, Anticancer research.

[50]  H. Herschman,et al.  Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes. , 1981, Proceedings of the National Academy of Sciences of the United States of America.